Alzheimer's Study Targets Early Memory Loss
Participants needed for groundbreaking study on the progression of Alzheimer’s diseaseJanuary 6, 2011 | by Erin White
Researchers will use imaging techniques and biomarker measures in blood and cerebrospinal fluid specially developed to track changes in the living brain. The goal is to identify who is at risk for Alzheimer’s, track progression of the disease and devise tests to measure the effectiveness of potential interventions.
Northwestern Medicine’s Cognitive Neurology and Alzheimer's Disease Center (CNADC) is one of several study sites led by the National Institute on Aging. The study is an expansion of the National Institutes of Health’s Alzheimer’s Disease Neuroimaging Initiative.
“This is an important study to develop ways physicians can detect the disease before the person has overt memory loss,” said Diana Kerwin, the principal investigator of the study at CNADC and assistant professor of geriatrics at Feinberg. “The earlier we can detect disease the better chance there is to prevent or delay the memory loss from happening at all. Early diagnosis is really going to be key as far as making any further breakthroughs into the treatment of Alzheimer’s disease and other memory disorders.”
Potential participants include men and women aged 55 to 90 with early signs of memory loss that does not currently affect their daily lives. Participants without signs of cognitive problems also can enroll in the control group of the study.
“By taking part in the study, someone who has Alzheimer’s disease in their family or is concerned about their own memory would be contributing to our scientific understanding of the early markers of Alzheimer’s disease pathology in the brain and also normal aging,” Kerwin said.
Another important aspect of the study is the sharing of data soon after it is obtained. Imaging data is posted to a publicly accessible database available to qualified researchers worldwide.
To find out more about this study contact Kristine Lipowski, the study’s project coordinator, at: (312) 503-2486.
Alzheimer’s Disease Neuroimaging Initiative is funded by the National Institutes of Health, The Food and Drug Administration, pharmaceutical, imaging, and clinical trial management companies and nonprofit organizations, including the Alzheimer’s Association and Alzheimer’s Drug Discovery Foundation, as well as from private donations.